1096 related articles for article (PubMed ID: 23925867)
21. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
22. Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.
Hohnloser SH; Camm J; Cappato R; Diener HC; Heidbuchel H; Lanz HJ; Mont L; Morillo CA; Smolnik R; Yin OQP; Kautzner J
Clin Cardiol; 2018 Apr; 41(4):440-449. PubMed ID: 29663464
[TBL] [Abstract][Full Text] [Related]
23. New oral anticoagulants for atrial fibrillation: a review of clinical trials.
O'Dell KM; Igawa D; Hsin J
Clin Ther; 2012 Apr; 34(4):894-901. PubMed ID: 22417716
[TBL] [Abstract][Full Text] [Related]
24. Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis.
Wang X; Ma Y; Hui X; Li M; Li J; Tian J; Wang Q; Yan P; Li J; Xie P; Yang K; Yao L
Cochrane Database Syst Rev; 2023 Apr; 4(4):CD010956. PubMed ID: 37058421
[TBL] [Abstract][Full Text] [Related]
25. Vitamin K antagonists versus antiplatelet therapy after transient ischaemic attack or minor ischaemic stroke of presumed arterial origin.
De Schryver EL; Algra A; Kappelle LJ; van Gijn J; Koudstaal PJ
Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD001342. PubMed ID: 22972051
[TBL] [Abstract][Full Text] [Related]
26. The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation.
Karthikeyan G; Connolly SJ; Ntsekhe M; Benz A; Rangarajan S; Lewis G; Yun Y; Sharma SK; Maklady F; Elghamrawy AE; Kazmi K; Cabral TTJ; Dayi H; Changsheng M; Gitura BM; Avezum A; Zuhlke L; Lwabi P; Haileamlak A; Ogah O; Chillo P; Paniagua M; ElSayed A; Dans A; Gondwe-Chunda L; Molefe-Baikai OJ; Gonzalez-Hermosillo JA; Hakim J; Damasceno A; Kamanzi ER; Musuku J; Davletov K; Connolly K; Mayosi BM; Yusuf S;
Am Heart J; 2020 Jul; 225():69-77. PubMed ID: 32474206
[TBL] [Abstract][Full Text] [Related]
27. Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial.
Geller BJ; Giugliano RP; Braunwald E; Murphy SA; Hanyok JJ; Jin J; Mercuri M; Antman EM; Ruff CT
Am Heart J; 2015 Oct; 170(4):669-74. PubMed ID: 26386790
[TBL] [Abstract][Full Text] [Related]
28. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis.
Robertson L; Kesteven P; McCaslin JE
Cochrane Database Syst Rev; 2015 Jun; (6):CD010956. PubMed ID: 26123214
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: systematic review and meta-analysis of 22 studies and 440 281 patients.
Silverio A; Di Maio M; Prota C; De Angelis E; Radano I; Citro R; Carrizzo A; Ciccarelli M; Vecchione C; Capodanno D; Galasso G
Eur Heart J Cardiovasc Pharmacother; 2021 Apr; 7(FI1):f20-f29. PubMed ID: 31830264
[TBL] [Abstract][Full Text] [Related]
30. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
Goette A; Merino JL; Ezekowitz MD; Zamoryakhin D; Melino M; Jin J; Mercuri MF; Grosso MA; Fernandez V; Al-Saady N; Pelekh N; Merkely B; Zenin S; Kushnir M; Spinar J; Batushkin V; de Groot JR; Lip GY;
Lancet; 2016 Oct; 388(10055):1995-2003. PubMed ID: 27590218
[TBL] [Abstract][Full Text] [Related]
31. Novel oral anticoagulants in atrial fibrillation: a meta-analysis of large, randomized, controlled trials vs warfarin.
Dogliotti A; Paolasso E; Giugliano RP
Clin Cardiol; 2013 Feb; 36(2):61-7. PubMed ID: 23338902
[TBL] [Abstract][Full Text] [Related]
32. Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial.
De Caterina R; Renda G; Carnicelli AP; Nordio F; Trevisan M; Mercuri MF; Ruff CT; Antman EM; Braunwald E; Giugliano RP
J Am Coll Cardiol; 2017 Mar; 69(11):1372-1382. PubMed ID: 28302288
[TBL] [Abstract][Full Text] [Related]
33. Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease.
Qamar A; Antman EM; Ruff CT; Nordio F; Murphy SA; Grip LT; Greenberger NJ; Yin OQP; Choi Y; Lanz HJ; Mercuri MF; Braunwald E; Giugliano RP
J Am Coll Cardiol; 2019 Jul; 74(2):179-189. PubMed ID: 31296289
[TBL] [Abstract][Full Text] [Related]
34. Antiplatelet versus anticoagulation treatment for patients with heart failure in sinus rhythm.
Shantsila E; Lip GY
Cochrane Database Syst Rev; 2016 Sep; 9(9):CD003333. PubMed ID: 27629776
[TBL] [Abstract][Full Text] [Related]
35. Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks.
Aguilar M; Hart R
Cochrane Database Syst Rev; 2005 Oct; (4):CD001925. PubMed ID: 16235290
[TBL] [Abstract][Full Text] [Related]
36. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.
Mahaffey KW; Wojdyla D; Hankey GJ; White HD; Nessel CC; Piccini JP; Patel MR; Berkowitz SD; Becker RC; Halperin JL; Singer DE; Califf RM; Fox KA; Breithardt G; Hacke W
Ann Intern Med; 2013 Jun; 158(12):861-8. PubMed ID: 23778903
[TBL] [Abstract][Full Text] [Related]
37. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial.
; Bousser MG; Bouthier J; Büller HR; Cohen AT; Crijns H; Davidson BL; Halperin J; Hankey G; Levy S; Pengo V; Prandoni P; Prins MH; Tomkowski W; Torp-Pedersen C; Wyse DG
Lancet; 2008 Jan; 371(9609):315-21. PubMed ID: 18294998
[TBL] [Abstract][Full Text] [Related]
38. Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias.
Bawazeer GA; Alkofide HA; Alsharafi AA; Babakr NO; Altorkistani AM; Kashour TS; Miligkos M; AlFaleh KM; Al-Ansary LA
Cochrane Database Syst Rev; 2021 Oct; 10(10):CD013504. PubMed ID: 34674223
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).
Bansilal S; Bloomgarden Z; Halperin JL; Hellkamp AS; Lokhnygina Y; Patel MR; Becker RC; Breithardt G; Hacke W; Hankey GJ; Nessel CC; Singer DE; Berkowitz SD; Piccini JP; Mahaffey KW; Fox KA;
Am Heart J; 2015 Oct; 170(4):675-682.e8. PubMed ID: 26386791
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
